Chronic allograft nephropathy: What have we learned from protocol biopsies?

Transplantation

Volumn 85, Issue 7 SUPPL., 2008, Pages

  Bosmans, Jean Louis ^a   Ysebaert, Dirk K ^a   Verpooten, Gert A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Calcineurin inhibitor nephrotoxicity; Chronic allograft nephropathy; Protocol biopsies; Renal allograft; Subclinical rejection

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ATROPHY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; NEPHROTOXICITY; PATHOPHYSIOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TREATMENT RESPONSE;

ATROPHY; BIOPSY; CHRONIC DISEASE; FIBROSIS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 42049107147     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318169c5d0     Document Type: Review

References (49)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
3. Isoniemi HM, Krogerus L, von Willebrand E, et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155.
4. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
5. Nankivell BJ, Chapmann JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
6. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
7. Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
8. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 2003; 76: 969.
9. Schwarz A, Gwinner W, Hiss M, et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5: 1992.
10. Lehtonen SRK, Taskinen EI, Isoniemi HM. Histological alterations in implant and one-year protocol biopsy specimens of renal allografts. Transplantation 2001; 72: 1138.
11. Bosmans JL. The development of interstitial fibrosis in cadaveric renal allografts: Prospective clinico-pathological observations and pathophysiological implications. PhD thesis, University of Antwerp 2001. ISBN 90-72812-11-5.
12. Lopes JA, Moreso F, Riera L, et al. Evaluation of pre-implantation kidney biopsies: Comparison of Banff criteria to a morphometric approach. Kidney Int 2005; 67: 1595.
13. Serón D, Carrera M, Grinyó JM, et al. Relationship between donor renal interstitial surface and post-transplant function. Nephrol Dial Transplant 1993; 8: 539.
14. Bosmans JL, Woestenburg AT, Ysebaert DK, et al. Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal grafts. Transplantation 2000; 69: 2388.
15. Nicholson ML, McCulloch TA, Harper SJ, et al. Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 1082.
16. Seron D, Moreso F, Condom E, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310.
17. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years post-transplant. J Am Soc Nephrol 1998; 9: 482.
18. Kuypers DRJ, Chapman JR, O'Connell PJ, et al. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 1222.
19. Yilmaz S, Tomlanovich S, Mathew T, et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end-point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773.
20. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130.
21. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506.
22. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
23. Nankivell BJ, Borrows RJ, Fung CLS, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242.
24. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Clinico-pathologic correlations using the Banff schema. Transplantation 1995; 59: 511.
25. Nickerson P, Jeffery JR, Gough J, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrol 1999; 10: 1801.
26. Shapiro R, Randhawa P, Jordan ML, et al. An analysis of early renal transplant protocol biopsies: The high incidence of subclinical tubulitis. Am J Transplant 2001; 1: 47.
27. Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year single experience at a single center. Am J Transplant 2005; 5: 1354.
28. Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046.
29. Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP project. Kidney Int 2001; 60: 1998.
30. Moreso F, Serón D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78: 1064.
31. Isoniemi H, Taskinen E, Haÿry P. Histological chronic allograft damage accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 1195.
32. Serón D, Moreso F, Ramón JM, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849.
33. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(3 suppl 3): 759.
34. Antonovch TT, Sabnis SG, Austin HA, et al. Cyvclosporine A induced arteriolopathy. Transplant Proc 1988; 20(3 suppl 3): 951.
35. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674.
36. Gwinner W, Suppa S, Mengel M, et al. Early calcifications of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 2005; 5: 1934.
37. van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17: 881.
38. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305.
39. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK 506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
40. Badid C, Vincent M, McGregor B, et al. Mycopenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51.
41. Azuma H, Binder J, Heemann U, et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460.
42. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945.
43. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
44. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
45. Halloran PF, Langone AJ, Helderman JH, et al. Assessing long-term nephron loss: Is it time to kick the CAN grading system? Am J Transplant 2004; 4: 1729.
46. Serón D, Moreso F, Fulladosa X, et al. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727.
47. Racusen L, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
48. Sorof JM, Vartanian JK, Olson JL, et al. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection. Transplantation 1995; 60: 1215.
49. Colvin RB. Chronic allograft nephropathy: Perspective. N Engl J Med 2003; 349: 2288.